secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0001213900-22-034635
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics shareholders reject reverse stock split; Nasdaq compliance at risk
--------------------------------------------------------------------------------

- Shareholders re-elected directors Robb Knie, David Sarnoff, Graig Springer, Wayne Linsley.
- Ratified Withum as independent auditor for FY2022; approved 2022 Omnibus Equity Incentive Plan.
- Reverse stock split proposal (1:2 to 1:20) failed, with 13,162,362 for, 3,116,563 against.
- Nasdaq minimum bid price compliance deadline is June 28, 2022; company considers special meeting to revisit reverse split.
- Failure to regain compliance could result in delisting from Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390022034635/0001213900-22-034635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390022034635/ea161987-8k_hoththera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-034635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer